Three articles reported a better OS of HER2-low compared to HER2-zero cases, with Peiffer et al. [19] finding a better OS for stage III and stage IV BC, and Martinez-Cannon et al. [21] finding a better OS when positive for hormone receptors (HR) or if ≥2 lines of treatment received. This evidence concerns the gene ERBB2 and breast cancer.